the Effect of Integrated Neuomuscular Inhibition Technique on Adult Females With Cervicogenic Headache
- Conditions
- Cervicogenic Headache
- Interventions
- Drug: Muscle relaxants tizanidineOther: integrated neuromuscular inhibition technique
- Registration Number
- NCT07025187
- Lead Sponsor
- Kafrelsheikh University
- Brief Summary
The purpose of the current study is investigating the effect of integrated neuromuscular inhibition technique on adult females with cervicogenic headache.
Methods: Forty females with cervicogenic headache will be recruited. Patients will be randomly assigned into two groups, group A and group B . Patients in both groups will receive a traditional medical treatment, but group (B) will receive additional integrated neuromuscular inhibition technique.
- Detailed Description
Measurements will be taken for all participants before the start of treatment program then after the end of 4 weeks treatment program, then after another 4 weeks of follow up.all patients will be evaluated for headache pain intensity, cervicogenic headache frequency, cervicogenic headache duration, cervical range of motion in all directions, the isometric endurance capacity of sternocledomastoid and anterior scalene, kinesiophobia, neck disability, and headache impact test-6.
All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day.
Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 40
1 - A diagnosis of CGH will be made by an experienced neurologist as per the International Classification of Headache Disorders 3rd edition (ICHD-3) , but not including occipital nerve blockage 2-Additional inclusion criteria will include female patients aged> 18 years and<60 years.
3-headache intensity ≥ 3 on eleven-point numerical rating scale at enrolment. 4-at least three-month history of headache with a mean frequency of > 1/week. 5-hypomobility of the upper cervical spine (C0 to C3) on manual examination; and reproduction of the headache on palpation of the upper cervical spine (C0 to C3).
6-In addition, patients should exhibit active trigger points within the suboccipital, and upper trapezius muscles, ipsilaterally over the symptomatic side reproducing their headache symptoms .
-
Patients will be excluded if they have any of the following:
- cervical radiculopathy,
- history of neck, shoulder trauma or surgery,
- history of intervention for head or neck pain within the previous 3 months,
- A diagnosis of other types of headaches using the criteria of ICHD-3.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control group Muscle relaxants tizanidine All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day. experimental group Muscle relaxants tizanidine Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month. experimental group integrated neuromuscular inhibition technique Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month.
- Primary Outcome Measures
Name Time Method headache frequency Baseline, 4 weeks and 8 weeks Cervicogenic headache frequency, which is a self-administered outcome variable, will be identified by asking patients to enter their CGH pain experience in a medical logbook every evening to find the number of painful days in the last week, ranging from 0 to 7 days.
headache duration Baseline, 4 weeks and 8 weeks . Headache duration will be measured as the total hours of headache in the last week, with six possible ranges: (1) 0 to 5 hours, (2) 6 to10 hours, (3) 11 to 15 hours, (4) 16 to 20 hours, (5) 21 to 25 hours, or (6) 26 or more hours
headache pain intensity Baseline, 4 weeks and 8 weeks . headache pain intensity measured by 11-Numerical rating scale
cervical ROM in all directions Baseline, 4 weeks and 8 weeks . Cervical right and left lateral flexion, extension, and flexion ROM will be measured using the iPhone clinometer application, whereas cervical right and left rotation ROM will be measured using the iPhone compass application.
- Secondary Outcome Measures
Name Time Method kinesiophobia Baseline, 4 weeks and 8 weeks . kinesiophobia will be measured by Arabic Tampa scale
Isometric endurance capacity of sternocledomastoid and anterior scalene Baseline, 4 weeks and 8 weeks . The isometric endurance capacity of the sternocleidomastoid and anterior scalene will be assessed using an isometric test.
the impact of headaches on patients' lives Baseline, 4 weeks and 8 weeks . the impact of headaches on patients' lives measured by Arabic headache impact test-6.
neck disability Baseline, 4 weeks and 8 weeks . the neck disability will be measured by Arabic neck disability index
Trial Locations
- Locations (1)
Khalid enb elwaleed polyclinic
🇪🇬Tanta, Algharbia, Egypt